Cartalax 20mg

Cartalax – 20mg

Lyophilized Peptide • Research Use Only

Description: Cartalax (also known as AED, T‑31, or Ala‑Glu‑Asp) is a synthetic tripeptide studied for its tissue‑specific regulatory effects, particularly in cartilage, joint structures, and musculoskeletal cellular longevity. Research models suggest that Cartalax may support collagen synthesis, protect connective tissues from age‑related degeneration, and help maintain joint resilience under mechanical or oxidative stress.

As a bioregulatory peptide, Cartalax is of interest for its potential to influence gene expression, normalize extracellular matrix composition, and promote long‑term tissue homeostasis.

Specifications:

• Peptide: Cartalax (AED / T‑31 / Ala‑Glu‑Asp)

• Purity: ≥99.7%

• Form: Lyophilized powder

• Quantity: 20mg per vial

• Storage:

  • Store at –20°C (–4°F)

  • After reconstitution, refrigerate at 2–8°C (36–46°F); use within 30 days

• Grade: Research Use Only — Not for human consumption, therapeutic, or diagnostic use

Research Focus Areas:

• Cartilage regeneration — Type II collagen and proteoglycan synthesis

• Joint and mobility support — structural reinforcement and elasticity studies

• Anti‑inflammatory activity — cytoprotective and membrane‑stabilizing effects

• Cellular & mitochondrial health — ROS mitigation and senescence‑delay models

• Bioregulatory gene expression — extracellular matrix normalization

Mechanistic Interest: Cartalax is studied for its ability to act at the cellular regulatory level, rather than functioning as a broad anti‑inflammatory agent. Research suggests it may modulate gene expression, support extracellular matrix balance, and promote connective‑tissue homeostasis, making it a notable subject in regenerative and anti‑aging research.

NOTICE: FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION.